Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PAM | P19021 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10012816 | 0.96 | DGKA (0.39) | TSHRDGKACYP1A2PAMMAPT | |
| SCHEMBL10012609 | 0.94 | DGKA (0.42) | TSHRDGKACYP1A2PAMMAPT | |
| SCHEMBL10010090 | 0.93 | TSHR (0.46) | TSHRDGKACYP1A2PAMALDH1A1 | |
| SCHEMBL10012056 | 0.92 | ADRA2A (0.35) | TSHRMAPTALDH1A1 | |
| SCHEMBL28602342 | 0.91 | DGKA (0.44) | TSHRDGKACYP1A2PAMMAPT | |
| SCHEMBL10012818 | 0.89 | TSHR (0.41) | TSHRPAMALDH1A1MEN1KMT2A | |
| SCHEMBL10012611 | 0.88 | PAM (0.42) | TSHRDGKAPAMALDH1A1MEN1 | |
| SCHEMBL10012059 | 0.85 | EGLN1 (0.38) | TSHRPAMMAPTALDH1A1LMNA | |
| SCHEMBL10011231 | 0.80 | TSHR (0.38) | TSHRDGKACYP1A2PAMMAPT | |
| SCHEMBL23623232 | 0.77 | ALDH1A1 (0.39) | TSHRALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9130244-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| EP-2908376-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2479831-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | SLC8A1, OR10J3, SLC8B1 | TSHR 3669/4885DGKA 1127/4885CYP1A2 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.